About Mural Oncology
Mural Oncology is a company based in Waltham (United States) founded in 2023 was acquired by XOMA Corporation in August 2025.. The company has 116 employees as of December 31, 2024. Mural Oncology offers products and services including MURA-7012, MURA-8518, and Nemvaleukin Alfa. Mural Oncology operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Waltham, United States
- Employees 116 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mural Oncology Plc
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-128.51 M38.05as on Dec 31, 2024
-
EBITDA
$-134.75 M29.84as on Dec 31, 2024
-
Latest Funding Round
- Investors
-
Employee Count
116
as on Dec 31, 2024
-
Acquired by
XOMA Corporation
(Aug 20, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Mural Oncology
Mural Oncology is a publicly listed company on the NASDAQ with ticker symbol MURA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Mural Oncology
Mural Oncology offers a comprehensive portfolio of products and services, including MURA-7012, MURA-8518, and Nemvaleukin Alfa. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Preclinical program developing cancer treatments via engineered cytokines
Preclinical initiative for advancing cancer immunotherapy options
Engineered IL-2 variant for treating advanced solid tumors in trials
Unlock access to complete
Funding Insights of Mural Oncology
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Mural Oncology
Mural Oncology has secured backing from 1 investor. Prominent investors backing the company include XOMA Corporation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Antibody-based therapeutics are developed for endocrine and metabolic diseases.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Mural Oncology
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Mural Oncology
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mural Oncology Comparisons
Competitors of Mural Oncology
Mural Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mural Oncology
Frequently Asked Questions about Mural Oncology
When was Mural Oncology founded?
Mural Oncology was founded in 2023.
Where is Mural Oncology located?
Mural Oncology is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Who is the current CEO of Mural Oncology?
Caroline J Loew is the current CEO of Mural Oncology.
How many employees does Mural Oncology have?
As of Dec 31, 2024, the latest employee count at Mural Oncology is 116.
What does Mural Oncology do?
Mural Oncology was founded in 2023 and is headquartered in Waltham, United States. Focus is placed on the biotechnology sector, where cytokine biology, immune cell modulation, and protein engineering are utilized to create immunotherapies targeted at cancer. Operations involve research and development of these therapies to address oncology needs, with activities centered in the U.S. market.
Who are the top competitors of Mural Oncology?
Mural Oncology's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Mural Oncology offer?
Mural Oncology offers MURA-7012, MURA-8518, and Nemvaleukin Alfa.
Is Mural Oncology publicly traded?
Yes, Mural Oncology is publicly traded on NASDAQ under the ticker symbol MURA.
Who are Mural Oncology's investors?
Mural Oncology has 1 investor. Key investors include XOMA Corporation.
What is Mural Oncology's ticker symbol?
The ticker symbol of Mural Oncology is MURA on NASDAQ.